After adjusting for maternal age, duration of diabetes, BMI, and daily dose of insulin, CSII therapy was associated with elevated risks of neonatal jaundice (adjusted odds ratio [aOR] 2.76, 95% confidence interval [CI] 1.16–6.57), and NICU (aOR 3.73, 95% CI 1.24–11.16), compared with the MDI group. Here, INS is linked to diabetes mellitus.